Literature DB >> 15623706

Treatment of low-grade oligodendroglial tumors without radiotherapy.

Yoshinori Higuchi1, Yasuo Iwadate, Akira Yamaura.   

Abstract

The authors prospectively treated 18 consecutive patients with low-grade oligodendroglial tumors without postoperative radiotherapy. The treatment strategy was as follows: follow-up after total resection and chemotherapy after subtotal resection or biopsy. All patients were alive and 17 patients (94%) were progression-free after a median follow-up of 4.7 years. The results suggested that radiotherapy could be postponed until clinical progression in the treatment of low-grade oligodendroglial tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15623706     DOI: 10.1212/01.wnl.0000147243.02317.28

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.

Authors:  Matthieu Peyre; Stéphanie Cartalat-Carel; David Meyronet; Damien Ricard; Anne Jouvet; Johan Pallud; Karima Mokhtari; Jacques Guyotat; Emmanuel Jouanneau; Marie-Pierre Sunyach; Didier Frappaz; Jérôme Honnorat; François Ducray
Journal:  Neuro Oncol       Date:  2010-05-20       Impact factor: 12.300

2.  Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Authors:  Yasuo Iwadate; Tomoo Matsutani; Yuzo Hasegawa; Natsuki Shinozaki; Yoshinori Higuchi; Naokatsu Saeki
Journal:  J Neurooncol       Date:  2010-08-19       Impact factor: 4.130

Review 3.  Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?

Authors:  Lauren R Schaff; Andrew B Lassman
Journal:  Semin Radiat Oncol       Date:  2015-02-23       Impact factor: 5.934

Review 4.  The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma : A systematic review and evidence-based clinical practice guideline.

Authors:  Mateo Ziu; Steven N Kalkanis; Mark Gilbert; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

5.  Recent innovations in the management of low-grade gliomas.

Authors:  Shaheryar Hafeez; Robert Cavaliere
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

6.  Selection of chemotherapy for glioblastoma expressing O(6)-methylguanine-DNA methyltransferase.

Authors:  Yasuo Iwadate; Tomoo Matsutani; Yuzo Hasegawa; Natsuki Shinozaki; Takashi Oide; Toru Tanizawa; Yukio Nakatani; Naokatsu Saeki; Shuichi Fujimoto
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

7.  Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas.

Authors:  Catherine R Garcia; Stacey A Slone; Thomas Pittman; William H St Clair; Donita D Lightner; John L Villano
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

8.  A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma.

Authors:  Nancy Ann Oberheim Bush; Jacob S Young; Yalan Zhang; Cecilia L Dalle Ore; Annette M Molinaro; Jennie Taylor; Jennifer Clarke; Michael Prados; Steve E Braunstein; David R Raleigh; Susan M Chang; Mitchel S Berger; Nicholas A Butowski
Journal:  J Neurooncol       Date:  2021-06-14       Impact factor: 4.130

9.  Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography.

Authors:  Yasuo Iwadate; Natsuki Shinozaki; Tomoo Matsutani; Yoshio Uchino; Naokatsu Saeki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-02-04       Impact factor: 10.154

10.  Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas.

Authors:  Araceli Henares-Molina; Sebastien Benzekry; Pedro C Lara; Marcial García-Rojo; Víctor M Pérez-García; Alicia Martínez-González
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.